Catalyst Wire Dossier Catalyst Wire Dossier
EMA approval · 2026-01-26

EMA Authorised: Levetiracetam Actavis Group (levetiracetam) — Actavis Group PTC ehf

View source ↗

Summary

EU marketing authorisation granted for Actavis Group PTC ehf's generic levetiracetam for epilepsy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Levetiracetam Actavis Group (levetiracetam)

Snippet

Status: Authorised. Therapeutic area: Epilepsy. MAH: Actavis Group PTC ehf. Decision date: 22/01/2026